Author Archives: emiliansnarski

AHSCT is better choice than DMDs in MS as a treatment of cases progressing after first line treatment – multicenter randomised trial.

After few decades of knowledge supported by many one-arm, non-randomised, one-center trials. Finally the randomised trial showing that AHSCT in better in MS than DMDs. Full text here: https://www.ncbi.nlm.nih.gov/pubmed/30644983 Advertisements

Posted in Uncategorized | Leave a comment

CPX-351 (Vyxeos) – new drug that improves treatment in older patients with secondary AML

Great news for older patients (over 60) with AML – there is a new combination drug that improves the chances of cure and survival. The long term survival is almost twice as good as the survial after the standard chemotherapy. … Continue reading

Posted in Uncategorized | Leave a comment

Complementary Medicine (alternative medicine) not so good for cancer patients

Many times I have been asked this question – and what if alternative medicine does work against cancer and we (the medical establishment) just block the results from surfacing? We do not. This study published in JAMA last year shows … Continue reading

Posted in Uncategorized | Leave a comment

Patient Problem Based Learning – new approach to medical classes

Problem based learning bases on solving defined problems found in trigger material. I thought about a way of simple implementation this strategy of learning into clinical practice of teaching my students. As patients are different every time I thought how … Continue reading

Posted in Uncategorized | Leave a comment

Hematopoietic stem cell transplantation in Multiple Sclerosis – effective 1st, 2nd and 3rd line treatment

During EBMT 2018 there were pivotal data presented that show that multiple sclerosis can be effectively treated with hematopoietic stem cell transplantation – and HSCT is effective as 1st, 2nd and 3rd line treatment. The most crucial data comes from … Continue reading

Posted in Uncategorized | Leave a comment

Cord Blood News – Trochę nowości o krwi pępowinowej

I have prepared (in polish) new presentation on news and progress in clinical use of cord blood. Time will tell what it will be used to – I am sure that there are some properties that are hard to replicate … Continue reading

Posted in Uncategorized | Leave a comment

FDA Approves CAR-T Cell Product for Acute Lymphoblastic Leukemia

This is the moment which is important – the CART cells are finally acknowledged by FDA – which means that they can be used as treatment. The price – still too high for them to be used widely – hopefully … Continue reading

Posted in Uncategorized | Leave a comment

Calcium blockers improve effect of chemotherapy in pancreatic cancer.

Dr Leszek Kraj, a colleague from our department, has just presented results of a new very interesting study during the 2017 Annual Meeting of ASCO (American Society of Clinical Oncology). The study analyzed the outcomes of patients with pancreatic cancer. … Continue reading

Posted in Uncategorized | Leave a comment

Lecture – Stem cells in neurology

There is a new lecture online on the use of stem cells in neurology. Download: 2017 Komórki macierzyste dla neurologów online    

Posted in Uncategorized | Leave a comment

“Lame will walk” – GREAT NEWS FOR CIDP PATIENTS on EBMT 2017 – update on autoimmune diseases.

I have just returned from the EBMT 2017 conference. I have met with most prominent world scientist in field of HSCT – and I am truly amazed by the results that were presented. Here are the most important observations: CIDP … Continue reading

Posted in Uncategorized | Leave a comment